Q1 EPS Estimates for FibroBiologics Increased by Analyst

FibroBiologics Inc. (NASDAQ:FBLG) – HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for FibroBiologics in a research note issued to investors on Thursday, February 26th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.07) per share for the quarter, up from their previous estimate of ($0.10). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.50) EPS and FY2029 earnings at ($0.65) EPS.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a report on Thursday, January 22nd. D. Boral Capital dropped their target price on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.50.

FibroBiologics Stock Up 16.2%

Shares of FibroBiologics stock opened at $0.33 on Monday. FibroBiologics has a 52 week low of $0.22 and a 52 week high of $1.53. The business has a 50 day moving average price of $0.29 and a 200-day moving average price of $0.39. The company has a market cap of $22.21 million, a PE ratio of -0.78 and a beta of -0.69.

FibroBiologics (NASDAQ:FBLG) last issued its earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.06.

Insider Transactions at FibroBiologics

In other FibroBiologics news, General Counsel Ruben A. Garcia acquired 140,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $0.34 per share, with a total value of $47,600.00. Following the completion of the acquisition, the general counsel owned 140,000 shares of the company’s stock, valued at $47,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 13.00% of the company’s stock.

Institutional Investors Weigh In On FibroBiologics

A number of institutional investors have recently made changes to their positions in FBLG. AQR Capital Management LLC purchased a new position in shares of FibroBiologics in the first quarter worth about $29,000. XTX Topco Ltd grew its position in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares during the last quarter. Ethos Financial Group LLC lifted its position in FibroBiologics by 100.0% in the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after purchasing an additional 24,424 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of FibroBiologics during the second quarter valued at approximately $37,000. Finally, Marshall Wace LLP purchased a new stake in shares of FibroBiologics during the second quarter valued at approximately $49,000.

More FibroBiologics News

Here are the key news stories impacting FibroBiologics this week:

• Positive Sentiment: HC Wainwright sharply raised EPS forecasts across 2026–2029 and cut expected near‑term losses (Q1–Q4 2026 now modeled around ($0.07)–($0.08); FY2026 now ($0.29) vs prior ($0.45)), and left a “Buy” rating with a $4 target — a clear analyst vote of confidence that likely lifted sentiment. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Company narrative: FibroBiologics is positioned to transition into a clinical‑stage company, which is a material operational milestone that can unlock investor interest, potential collaborations, and later-stage valuation re‑rating as clinical data milestones approach. FBLG: Ready to Transition to Clinical-Stage Company
• Neutral Sentiment: HC Wainwright also provided a longer‑horizon forecast (including FY2030 estimates) — useful for modelers but farther out and more uncertain; long‑term forecasts can support upside case but carry execution risk. HC Wainwright Forecasts FibroBiologics FY2030 Earnings
• Negative Sentiment: D. Boral Capital cut its price target to $7.00, signaling reduced near‑term upside compared with prior expectations; the cut injects caution and shows analysts remain divided on timing/scale of commercial or clinical progress. D. Boral Capital Cuts FibroBiologics Price Target

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.